{"product_id":"cst-90005s","title":"CST,  90005S, CD38 (HIT2) Mouse Monoclonal Antibody (FITC Conjugate)","description":"Monoclonal Antibody for studying CD38. Validated for Flow Cytometry (Live). Highly specific and rigorously validated in-house, CD38 (HIT2) Mouse Monoclonal Antibody (FITC Conjugate) (CST #90005) is ready to ship.\n\n\u003cb\u003eProduct Usage Information\u003c\/b\u003e\nFlow Cytometry (Live): 1:20\n\u003cb\u003eStorage\u003c\/b\u003e\nSupplied in 10 mM NaH2PO4, 150 mM NaCl, 0.09% NaN3, 0.1% gelatin, pH 7.2. This product is stable for 12 months when stored at 4ºC. Do not aliquot the antibody. Protect from light. Do not freeze.\n\u003cb\u003eProtocol\u003c\/b\u003e\nAvailable protocols: Flow Cytometry (Live)\n\u003cb\u003eSpecificity \/ Sensitivity\u003c\/b\u003e\nCD38 (HIT2) Mouse Monoclonal Antibody (FITC Conjugate) recognizes endogenous levels of total CD38 protein. This antibody conjugate detects an epitope within the extracellular domain.\nSpecies Reactivity: Human\n\u003cb\u003eSource \/ Purification\u003c\/b\u003e\nThis monoclonal antibody was purified from tissue culture supernatant via affinity chromatography. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation.\n\u003cb\u003eBackground\u003c\/b\u003e\nCyclic ADP-ribose hydrolase 1 (CD38) is a transmembrane protein involved in several important biological processes, including immune response, insulin secretion, and social behavior. Originally described as a glycosylated immune cell surface marker, additional research determined that CD38 is a multifunctional enzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD (1,2). Under acidic conditions, CD38 also catalyzes the synthesis of nicotinic acid adenine dinucleotide phosphate (NAADP) from NADP . Both cADPR and NAADP act as calcium ion mobilizing messengers that target different intracellular Ca stores (3-6). Since CD38 is the primary mammalian NAD glycohydrolase responsible for NAD metabolism, CD38 may be a valuable therapeutic target for treatment of metabolic diseases regulated by NAD -dependent pathways (7,8). CD38 has also been considered a possible therapeutic target for antibody-mediated therapy for myeloma and chronic lymphocytic leukemia (9-11).\n\u003cb\u003eAlternate Names\u003c\/b\u003e\n2'-phospho-ADP-ribosyl cyclase; 2'-phospho-ADP-ribosyl cyclase\/2'-phospho-cyclic-ADP-ribose transferase; 2'-phospho-cyclic-ADP-ribose transferase; ADP-ribosyl cyclase 1; ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase; ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 1; ADPRC 1; ADPRC1; cADPr hydrolase 1; CD38; CD38 antigen (p45); CD38 molecule; cluster of differentiation 38; Cyclic ADP-ribose hydrolase 1; ecto-nicotinamide adenine dinucleotide glycohydrolase; NAD(+) nucleosidase; T10\n\n\u003cb\u003eSpecification\u003c\/b\u003e\n\nREACTIVITY: H\nSENSITIVITY: Endogenous\nSource\/Isotype: Mouse IgG1 kappa","brand":"CST","offers":[{"title":"Default Title","offer_id":46800554655913,"sku":"90005S","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-90005s","provider":"Iright","version":"1.0","type":"link"}